Characterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgrounds Ma, Yixuan , 1991- (VerfasserIn) Junghanß, Christian , 1969- (AkademischeR BetreuerIn) Sendler, Matthias , 1980- (AkademischeR BetreuerIn) Jaster, Robert , 1964- (AkademischeR BetreuerIn) Universität Rostock (Grad-verleihende Institution) Universitätsmedizin Rostock (Grad-verleihende Institution) Text theses Text Hochschulschrift 2022 26 September 2022 eng electronic resourceremoteComputermedienOnline-Ressourceapplication/pdf1 Online-Ressource (106 Seiten) Illustrationen, Diagramme Key proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the above-mentioned key protein inhibitors on various PDAC cell lines, and to explore the effect of aberrations in the target genes of the inhibitors on the efficacy of the corresponding inhibitors by applying whole-exome sequencing (WES) and RNA sequencing (RNA-seq).<eng> Open Access Urheberrechtsschutz 1.0 vorgelegt von Yixuan Ma Enthält Zeitschriftenartikel The results of the dissertation presented here have been published in peer-reviewed journals with impact factor points. Work I: Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-Ali, R.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4409. https://doi.org/10.3390/ijms23084409 Impact Factor 2022: 5.924; Work II: The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Al-Ali, R.; Krake, S.; Radefeldt, M.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4295. https://doi.org/10.3390/ijms23084295 Impact Factor 2022: 5.924; Work III: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Schulz, B.; Trakooljul, N.; Al Ammar, M.; Sekora, A.; Sender, S.; Hadlich, F.; Zechner, D.; Weiss, F.U.; Lerch, M.M.; Jaster, R.; Junhanss, C.; Murua Escobar, H. Cancers 2022, 14, 4467. https://doi.org/10.3390/cancers14184467 Impact Factor 2022: 6.575 GutachterInnen: Christian Junghanß (Universitätsmedizin Rostock) ; Matthias Sendler (Universitätsmedizin Greifswald) ; Robert Jaster (Universitätsmedizin Rostock) Dissertation Universität Rostock 2023 Kumulative Dissertation 610 616.994 610 44.87 44.81 44.48 http://purl.uni-rostock.de/rosdok/id00004330 https://doi.org/10.18453/rosdok_id00004330 https://nbn-resolving.org/urn:nbn:de:gbv:28-rosdok_id00004330-3 https://d-nb.info/1297582942/34 Characterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgrounds--(DE-627)1851556184 urn:nbn:de:gbv:28-rosdok_id00004330-3 doi: 10.18453/rosdok_id00004330 oclc: 1389129488 ppn: (DE-627)1851554688